Citius OncologyCTOR -2.10%10 Receivables Turnover is 0.65 as of Mar. 2026. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 944 Drug Manufacturers companies, Citius Oncology ranks worse than 89.94% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Citius Oncology's Revenue for the
three
months ended in Mar. 2026 was $1.67 Mil. Citius Oncology's average Accounts Receivable for the
three
months ended in Mar. 2026 was $2.56 Mil.
Hence, Citius Oncology's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.65.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Citius Oncology Receivables Turnover Related Terms
Citius Oncology Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Citius Oncology's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTOR vs INCR, TLPH, ETST: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Citius Oncology Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Citius Oncology's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Citius Oncology (CTOR) has a Receivables Turnover of 0.65 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Citius Oncology and its competitors. According to the industry distribution chart, Citius Oncology ranks #849 out of 944 companies in the Drug Manufacturers industry, placing it in the top 89.9%.
Is Citius Oncology's Receivables Turnover too high?
Citius Oncology's current Receivables Turnover is 0.65. The Drug Manufacturers industry median Receivables Turnover is 5.07. Citius Oncology's value of 0.65 is 87.2% below this industry median. Based on the distribution chart, Citius Oncology ranks #849 out of 944 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's Receivables Turnover compare to INCR and TLPH?
According to the Drug Manufacturers industry distribution chart, Citius Oncology ranks #849 out of 944 companies for Receivables Turnover. This places Citius Oncology in the lower half of its industry. The industry median Receivables Turnover is 5.07. Citius Oncology's value of 0.65 is 87.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Citius Oncology's current Receivables Turnover of 0.65 is 87.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Citius Oncology and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Citius Oncology's current Receivables Turnover is 0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current Receivables Turnover of 0.65. The current Receivables Turnover is 0.65 and 87.2% below the Drug Manufacturers industry median of 5.07. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Citius Oncology (CTOR), the current Receivables Turnover is 0.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score
Get the complete analysis for CTOR
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTOR has been successfully added to your 
